Evidence map›Paper›PMID 40244491›Full record

ReviewInflammopharmacology2025

Gut microbiota and Parkinson's Disease: a new frontier in understanding neurological health.

Nishchhal Kumari, Veeranjaneyulu Addepalli, Aniket More, Ashwani Patil, Meghraj Suryawanshi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nishchhal KumariDr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, 411018, India.
Veeranjaneyulu AddepalliDr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, 411018, India.
Aniket MoreDr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, 411018, India.
Ashwani PatilDr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, 411018, India. ashwani.s.patil@dypvp.edu.in.ORCID http://orcid.org/0009-0003-7281-4716
Meghraj SuryawanshiDepartment of Pharmaceutics, Sandip Institute of Pharmaceutical Sciences (SIPS), Affiliated To Savitribai Phule Pune University (SPPU, Pune), Nashik, Maharashtra, 422213, India. suryawanshimeghraj917@gmail.com.ORCID http://orcid.org/0000-0003-3958-2813

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasingly recognized as a neurodegenerative disease with motor manifestations and progressive cognitive decline, PD has more frequently been linked to the gut microbiome. The gut-brain axis, a bidirectional communication system between the gut and brain, plays a crucial role in PD pathogenesis. Exploration of the intricacies in the interplay between PD and the gut microbiome, together with the important mechanisms involved, will form the basis of this review. Gut microbiome activities as contributors to PD actions include altered intestinal permeability, neuroinflammation, alpha-syn aggregation, oxidative stress, and neurotransmitter production. Gut-brain axis communication that is highly facilitated through immune, metabolic, and neural pathways enables communication between the gut and the brain. Recent evidence suggests that the disease may begin in the gut, with GI symptoms typically preceding loss of motor control. Research has shown a significant connection between Parkinson's disease and the gut microbiome, affecting disease onset, progression, and symptoms. Therapeutic strategies targeting the gut microbiome, such as probiotics, prebiotics, and FMT, may improve PD outcomes. Personalized medicine and neuroprotective therapies are promising for managing PD. Researchers are exploring the connection between the gut microbiome and PD to create new treatments for bettering the lives of those with the disease. By understanding the intricate relationship between the gut microbiome and PD, researchers can develop novel therapeutic approaches to improve the quality of life for individuals with this debilitating disease.

Indexed as

Gastrointestinal MicrobiomeParkinson DiseaseAnimalsBrainHumansPrebioticsProbioticsQuality of LifePrebioticsA-generating neurons in SNBidirectional communicationDegenerative neural disorderGut-brain axisGut dysbiosisParkinson's disease

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.